Implied SCHB Analyst Target Price: $25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2025
0mins
Should l Buy IDYA?
Source: NASDAQ.COM
ETF Analyst Target Prices: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $25.46, indicating a potential upside of 17.83% from its current trading price of $21.61. Notable underlying holdings with significant upside include Rapport Therapeutics Inc (RAPP), IDEAYA Biosciences Inc (IDYA), and Denali Therapeutics Inc (DNLI).
Investor Research Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 32.820
Low
30.00
Averages
49.86
High
79.00
Current: 32.820
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ideaya Biosciences Set to Release Darovasertib Trial Data
- Clinical Trial Data Release: Ideaya Biosciences is set to release joint trial results for Darovasertib with partner Servier on Monday, which is expected to significantly impact treatment for HLA A2-negative metastatic uveal melanoma and potentially expedite the approval process.
- Stock Surge: Ahead of the clinical data release, Ideaya's shares surged 20% overnight on Sunday, reflecting strong market anticipation for the upcoming Optimum-02 trial results and investor confidence in the drug's potential.
- Positive Analyst Ratings: Citigroup maintains a 'Buy' rating on Ideaya with a $65 price target, while Wedbush Securities raised its target from $49 to $52, indicating optimistic expectations surrounding the Optimum-02 trial results.
- Shift in Market Sentiment: According to Stocktwits, retail sentiment for IDYA shifted from 'bearish' to 'extremely bullish' over the past week, highlighting heightened investor focus and confidence in the critical data set to be released.
See More
U.S. Stocks Close Higher, Led by Tech Sector Gains
- Tech Sector Rally: Oracle's stock surged over 12%, leading a rebound in software stocks that propelled the overall market higher, indicating investor confidence in the tech sector's recovery, which may attract more capital inflows into this area.
- Economic Data Impact: U.S. March existing home sales fell 3.6% month-over-month to a 9-month low of 3.98 million, below the expected 4.05 million, and this weak data could influence the Fed's monetary policy decisions, increasing market expectations for rate cuts.
- Oil Price Volatility: Following President Trump's announcement of a full naval blockade of the Strait of Hormuz, WTI crude prices rose over 2%, although still below early highs, which could exacerbate global oil and fuel shortages, impacting related industry stock performance.
- Upcoming Earnings Season: Q1 earnings for the S&P 500 are projected to climb 12% year-over-year, but excluding the tech sector, earnings growth is only expected to be around 3%, the weakest in two years, reflecting market caution regarding profit growth.
See More
Mixed US Stock Performance Amid Soaring Oil Prices
- Oil Price Surge Impacts Market: Following President Trump's order to blockade the Strait of Hormuz, crude oil prices surged over 5%, putting pressure on the stock market, particularly affecting airline and cruise line stocks, indicating potential threats to corporate profits from oil price volatility.
- Software Stocks Rebound: Oracle's stock jumped over 8%, leading a rebound in software stocks, suggesting a positive market response to its newly launched utilities industry solutions, which may enhance the company's position in a competitive market.
- Weak Economic Data: March existing home sales in the US fell 3.6% month-over-month to a nine-month low of 3.98 million, below the expected 4.05 million, indicating weakness in the housing market that could negatively impact overall economic growth.
- Earnings Season Outlook: Q1 earnings for the S&P 500 are projected to rise 12% year-over-year, but excluding the technology sector, the increase is only 3%, the lowest in two years, reflecting cautious market sentiment regarding future profitability.
See More
Oil Price Surge Triggers Market Volatility
- Oil Price Surge: Following President Trump's order for a full naval blockade of the Strait of Hormuz, WTI crude oil prices have surged over 7%, which could exacerbate global oil and fuel shortages, impacting market supply-demand dynamics.
- Mixed Market Performance: While the S&P 500 index is up 0.05%, the Dow Jones Industrial Average has fallen by 0.39%, indicating market sensitivity to oil price fluctuations that may lead to investor sentiment instability.
- Earnings Expectations: According to Bloomberg Intelligence, Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the increase is only 3%, highlighting overall earnings growth weakness.
- Airline Stocks Decline: Due to rising oil prices, airline and cruise line stocks have generally fallen, with Carnival and Norwegian Cruise Line both down over 3%, reflecting the potential threat of high oil prices on corporate profits.
See More
IDEAYA and Servier Announce Positive Clinical Trial Results
- Clinical Trial Success: The OptimUM-02 trial conducted by IDEAYA and Servier demonstrated that the combination of Darovasertib and Crizotinib significantly improved median progression-free survival (PFS) to 6.9 months compared to 3.1 months in the ICT arm, reducing the risk of disease progression by 58%, laying the groundwork for a New Drug Application (NDA).
- Increased Patient Response Rates: The overall response rate (ORR) in the Darovasertib combination group was 37.1%, significantly higher than the 5.8% in the ICT group, showcasing the treatment's effectiveness and potentially attracting more investor interest.
- Good Safety Profile: The combination therapy was generally well-tolerated with a manageable safety profile consistent with prior reports, indicating that patient safety risks are controllable in future clinical applications, which could enhance market confidence.
- Future Development Plans: IDEAYA expects to submit an NDA to the FDA in the second half of 2026 and plans to provide additional details from the OptimUM-02 trial at a major medical conference in 2026, demonstrating the company's proactive approach to future market opportunities.
See More
IDEAYA and Servier Announce Positive Results for Darovasertib Clinical Trial
- Clinical Trial Success: The OptimUM-02 trial by IDEAYA and Servier demonstrated that the combination of darovasertib and crizotinib significantly improved median progression-free survival (PFS) to 6.9 months compared to 3.1 months in the control group for HLA-A*02:01-negative metastatic uveal melanoma patients, indicating substantial clinical significance.
- Risk Reduction for Patients: This combination therapy reduced the risk of disease progression by 58% (Hazard Ratio of 0.42, p-value <0.0001), providing a new treatment option for metastatic uveal melanoma patients and potentially changing the current treatment standards.
- Significant Response Rate: The overall response rate (ORR) in the darovasertib combination group was 37.1%, compared to only 5.8% in the control group (p-value <0.0001), highlighting the potential of this treatment regimen to improve patient outcomes.
- Future Plans: Based on these positive results, IDEAYA plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026 and will provide further study details at a major medical conference in 2026, advancing the clinical application of this therapy.
See More
Ideaya Biosciences Set to Release Darovasertib Trial Data
- Clinical Trial Data Release: Ideaya Biosciences is set to release joint trial results for Darovasertib with partner Servier on Monday, which is expected to significantly impact treatment for HLA A2-negative metastatic uveal melanoma and potentially expedite the approval process.
- Stock Surge: Ahead of the clinical data release, Ideaya's shares surged 20% overnight on Sunday, reflecting strong market anticipation for the upcoming Optimum-02 trial results and investor confidence in the drug's potential.
- Positive Analyst Ratings: Citigroup maintains a 'Buy' rating on Ideaya with a $65 price target, while Wedbush Securities raised its target from $49 to $52, indicating optimistic expectations surrounding the Optimum-02 trial results.
- Shift in Market Sentiment: According to Stocktwits, retail sentiment for IDYA shifted from 'bearish' to 'extremely bullish' over the past week, highlighting heightened investor focus and confidence in the critical data set to be released.
See More
U.S. Stocks Close Higher, Led by Tech Sector Gains
- Tech Sector Rally: Oracle's stock surged over 12%, leading a rebound in software stocks that propelled the overall market higher, indicating investor confidence in the tech sector's recovery, which may attract more capital inflows into this area.
- Economic Data Impact: U.S. March existing home sales fell 3.6% month-over-month to a 9-month low of 3.98 million, below the expected 4.05 million, and this weak data could influence the Fed's monetary policy decisions, increasing market expectations for rate cuts.
- Oil Price Volatility: Following President Trump's announcement of a full naval blockade of the Strait of Hormuz, WTI crude prices rose over 2%, although still below early highs, which could exacerbate global oil and fuel shortages, impacting related industry stock performance.
- Upcoming Earnings Season: Q1 earnings for the S&P 500 are projected to climb 12% year-over-year, but excluding the tech sector, earnings growth is only expected to be around 3%, the weakest in two years, reflecting market caution regarding profit growth.
See More
Mixed US Stock Performance Amid Soaring Oil Prices
- Oil Price Surge Impacts Market: Following President Trump's order to blockade the Strait of Hormuz, crude oil prices surged over 5%, putting pressure on the stock market, particularly affecting airline and cruise line stocks, indicating potential threats to corporate profits from oil price volatility.
- Software Stocks Rebound: Oracle's stock jumped over 8%, leading a rebound in software stocks, suggesting a positive market response to its newly launched utilities industry solutions, which may enhance the company's position in a competitive market.
- Weak Economic Data: March existing home sales in the US fell 3.6% month-over-month to a nine-month low of 3.98 million, below the expected 4.05 million, indicating weakness in the housing market that could negatively impact overall economic growth.
- Earnings Season Outlook: Q1 earnings for the S&P 500 are projected to rise 12% year-over-year, but excluding the technology sector, the increase is only 3%, the lowest in two years, reflecting cautious market sentiment regarding future profitability.
See More
Oil Price Surge Triggers Market Volatility
- Oil Price Surge: Following President Trump's order for a full naval blockade of the Strait of Hormuz, WTI crude oil prices have surged over 7%, which could exacerbate global oil and fuel shortages, impacting market supply-demand dynamics.
- Mixed Market Performance: While the S&P 500 index is up 0.05%, the Dow Jones Industrial Average has fallen by 0.39%, indicating market sensitivity to oil price fluctuations that may lead to investor sentiment instability.
- Earnings Expectations: According to Bloomberg Intelligence, Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the increase is only 3%, highlighting overall earnings growth weakness.
- Airline Stocks Decline: Due to rising oil prices, airline and cruise line stocks have generally fallen, with Carnival and Norwegian Cruise Line both down over 3%, reflecting the potential threat of high oil prices on corporate profits.
See More
IDEAYA and Servier Announce Positive Clinical Trial Results
- Clinical Trial Success: The OptimUM-02 trial conducted by IDEAYA and Servier demonstrated that the combination of Darovasertib and Crizotinib significantly improved median progression-free survival (PFS) to 6.9 months compared to 3.1 months in the ICT arm, reducing the risk of disease progression by 58%, laying the groundwork for a New Drug Application (NDA).
- Increased Patient Response Rates: The overall response rate (ORR) in the Darovasertib combination group was 37.1%, significantly higher than the 5.8% in the ICT group, showcasing the treatment's effectiveness and potentially attracting more investor interest.
- Good Safety Profile: The combination therapy was generally well-tolerated with a manageable safety profile consistent with prior reports, indicating that patient safety risks are controllable in future clinical applications, which could enhance market confidence.
- Future Development Plans: IDEAYA expects to submit an NDA to the FDA in the second half of 2026 and plans to provide additional details from the OptimUM-02 trial at a major medical conference in 2026, demonstrating the company's proactive approach to future market opportunities.
See More
IDEAYA and Servier Announce Positive Results for Darovasertib Clinical Trial
- Clinical Trial Success: The OptimUM-02 trial by IDEAYA and Servier demonstrated that the combination of darovasertib and crizotinib significantly improved median progression-free survival (PFS) to 6.9 months compared to 3.1 months in the control group for HLA-A*02:01-negative metastatic uveal melanoma patients, indicating substantial clinical significance.
- Risk Reduction for Patients: This combination therapy reduced the risk of disease progression by 58% (Hazard Ratio of 0.42, p-value <0.0001), providing a new treatment option for metastatic uveal melanoma patients and potentially changing the current treatment standards.
- Significant Response Rate: The overall response rate (ORR) in the darovasertib combination group was 37.1%, compared to only 5.8% in the control group (p-value <0.0001), highlighting the potential of this treatment regimen to improve patient outcomes.
- Future Plans: Based on these positive results, IDEAYA plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026 and will provide further study details at a major medical conference in 2026, advancing the clinical application of this therapy.
See More
